NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/08/2024
Back to search
Official data from USPTO
VELOXIS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079103548Class
5, 40, 41, 42, 44, 45
Filing
79103548
Registration
4212076
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
68
Latest update
11/08/2024
Trademark type
Combined
Nice classes
5, 40, 41, 42, 44, 45
Filing date
07/07/2011
Registration date
09/25/2012
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/14/2022
Last transaction
03/21/2023
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
Cary, NC, US
Examiner
EINSTEIN, MATTHEW
Law office
M60
Mark description
The mark consists of the wording "VELOXIS PHARMACEUTICALS" below two curved lines.
Holders and representatives
Holders
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals A/S
Representatives
Julia Anne Matheson Potomac Law Group, PLLC
Technical classification
Nice Classes
Class 5Class 40Class 41Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsimmunotherapeutic and immunosuppressive preparations for medical use for treatment of transplant patients; pharmaceutical preparations and drug delivery systemspharmaceutical modified release systemspharmaceutical controlled release systemscomprised of tabletsgranulespillssachetspowderscapsulessolutions or fluidsall of the above for use in the treatment of mental and physical disordersemergencies and traumasagingallergy and immunologyburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseasesdiseases and afflictions of the gastroenterological systemdiseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesdiseases in the obstetrical and gynecological fieldcancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the earnose and throatdiseases and afflictions in the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictions and generalized pain
Class 40
Treatment of materialsmillinggrindingmixingcompressingmelting of pharmaceuticalmedicinalbiotechnical and bacteriological substancespreparationsformulations and solutionsfor use in the pharmaceutical and medical industries
Class 41
Education and training servicesarranging and conducting of seminarsworkshopsconferenceslectures and congressesall in the medicalchemical and pharmaceutical fields
Class 42
Scientific and technological servicesscientific researchanalysis and testing in the field of medical sciencepharmacologybiotechnology and bacteriological areas and providing consultation and information relating thereto; design of drug delivery systems for medical use; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries
Class 44
Medical and pharmaceutical assistance and consultationmedical and pharmaceutical information servicesproviding medical and scientific research information in the field of pharmaceuticals
Class 45
Consultancy services regarding intellectual property; licensing of intellectual property; medical and pharmaceutical assistance and consultationincluding medical and pharmaceutical information services
Publications
History of USPTO decisions and trademark events.
68 publications found
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
07/21/2023
INPC
INVALIDATION PROCESSED
06/14/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/14/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/21/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/21/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/21/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/21/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/21/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
09/14/2022
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
09/14/2022
ES71
TEAS SECTION 71 RECEIVED
09/12/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
09/25/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
09/18/2021
RNWL
INTERNATIONAL REGISTRATION RENEWED
07/22/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
05/21/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/07/2020
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
10/11/2019
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
06/22/2019
INPC
INVALIDATION PROCESSED
06/22/2019
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/29/2019
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
09/29/2018
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
09/29/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/27/2018
ES75
TEAS SECTION 71 & 15 RECEIVED
09/24/2018
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
09/17/2018
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
08/03/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/18/2018
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/25/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/21/2016
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/26/2015
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/11/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/04/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/11/2013
FIMP
FINAL DISPOSITION PROCESSED
02/11/2013
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/25/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
09/25/2012
GPNX
NOTIFICATION PROCESSED BY IB
07/23/2012
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/10/2012
PUBO
PUBLISHED FOR OPPOSITION
07/10/2012
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/20/2012
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/20/2012
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/20/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/01/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/31/2012
XAEC
EXAMINER'S AMENDMENT ENTERED
05/31/2012
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/31/2012
GNEA
EXAMINERS AMENDMENT E-MAILED
05/31/2012
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/31/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/30/2012
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/30/2012
ALIE
ASSIGNED TO LIE
05/22/2012
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/10/2012
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/10/2012
RFNT
REFUSAL PROCESSED BY IB
12/19/2011
RFNT
REFUSAL PROCESSED BY IB
11/27/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/10/2011
RFRR
REFUSAL PROCESSED BY MPU
11/08/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/08/2011
CNRT
NON-FINAL ACTION WRITTEN
11/07/2011
RFRR
REFUSAL PROCESSED BY MPU
11/03/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/02/2011
CNRT
NON-FINAL ACTION WRITTEN
11/01/2011
MAFR
APPLICATION FILING RECEIPT MAILED
11/01/2011
DOCK
ASSIGNED TO EXAMINER
10/28/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/28/2011
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
10/27/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/27/2011
Continuous trademark protection
Get notified about every new filing that threatens VELOXIS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.